Inhibition of the renin-angiotensin system and atrial fibrillation in heart failure

HeartDrug

Volumn 5, Issue 4, 2005, Pages 214-219

  Palardy, Maryse ^a   Ducharme, Anique ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Atrial fibrillation; Congestive heart failure; Renin angiotensin system

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN; TRANDOLAPRIL; VALSARTAN;

CLINICAL TRIAL; DRUG EFFECT; ELECTROSTIMULATION; HEART ATRIUM; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; ION TRANSPORT; MEDICAL RESEARCH; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROSPECTIVE STUDY; REVIEW;

EID: 29144456589     PISSN: 14229528     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089602     Document Type: Review

References (82)

1. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA: Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994;271:840-844.
2. Veenhuyzen GD, Simpson CS, Abdollah H: Atrial fibrillation. CMAJ 2004;171:755-760.
3. Liu XK, Jahangir A, Terzic A, Gersh BJ, Hammill SC, Shen WK: Age- and sex-related atrial electrophysiologic and structural changes. Am J Cardiol 2004;94:373-375.
4. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW: Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998;32:695-703.
5. Middlekauff HR, Stevenson WG, Stevenson LW: Prognostic significance of atrial fibrillation in advanced heart failure. A study of 390 patients. Circulation 1991;84:40-48.
6. Pozzoli M, Cioffi G, Traversi E, Pinna GD, Cobelli F, Tavazzi L: Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm. J Am Coll Cardiol 1998;32:197-204.
7. Stevenson WG, Stevenson LW, Middlekauff HR, et al: Improving survival for patients with advanced heart failure: a study of 737 consecutive patients. J Am Coll Cardiol 1995;26:1417-1423.
8. Mathew J, Hunsberger S, Fleg J, McSherry SF, Williford W, Yusuf S: Incidence, predictive factors, and prognostic significance of supra-ventricular tachyarrhythmias in congestive heart failure. Chest 2000;118:914-922.
9. Crijns HJ, Tjeerdsma G, de Kam PJ, et al: Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. Eur Heart J 2000;21:1238-1245.
10. Stevenson WG, Stevenson LW, Middlekauff HR, et al: Improving survival for patients with atrial fibrillation and advanced heart failure. J Am Coll Cardiol 1996;28:1458-1463.
11. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ: Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(suppl 3):429S-456S.
12. Zarembski DG, Nolan PE Jr, Slack MK, Caruso AC: Treatment of resistant atrial fibrillation. A meta-analysis comparing amiodarone and flecainide. Arch Intern Med 1995;155:1885-1891.
13. Roy D, Talajic M, Dorian P, et al: Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000;342:913-920.
14. Slavik RS, Tisdale JE, Borzak S: Pharmacologic conversion of atrial fibrillation: a systematic review of available evidence. Prog Cardiovasc Dis 2001;44:121-152.
15. van Gelder IC, Hagens VE, Bosker HA, et al: A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-1840.
16. Hohnloser SH, Kuck KH, Lilienthal J: Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000;356: 1789-1794.
17. Wyse DG, Waldo AL, DiMarco JP, et al: A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-1833.
18. Opolski G, Torbicki A, Kosior DA, et al: Rate control vs rhythm control in patients with non-valvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 2004; 126:476-486.
19. Steinberg JS, Sadaniantz A, Kron J, et al: Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation 2004;109:1973-1980.
20. Blackshear JL, Safford RE: AFFIRM and RACE trials: implications for the management of atrial fibrillation. Card Electrophysiol Rev 2003;7:366-369.
21. Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial. Am Heart J 2002;144:597-607.
22. Rensma PL, Allessie MA, Lammers WJ, Bonke FI, Schalij MJ: Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs. Circ Res 1988; 62:395-410.
23. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA: Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995;92:1954-1968.
24. Wijffels MC, Kirchhof CJ, Dorland R, Power J, Allessie MA: Electrical remodeling due to atrial fibrillation in chronically instrumented conscious goats: roles of neurohumoral changes, ischemia, atrial stretch, and high rate of electrical activation. Circulation 1997;96: 3710-3720.
25. Le Grand BL, Hatem S, Deroubaix E, Couetil JP, Coraboeuf E: Depressed transient outward and calcium currents in dilated human atria. Cardiovasc Res 1994;28:548-556.
26. Bosch RF, Zeng X, Grammer JB, Popovic K, Mewis C, Kuhlkamp V: Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiovasc Res 1999;44:121-131.
27. Bosch RF, Zeng X, Grammer JB, Popovic K, Mewis C, Kuhlkamp V: Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiovasc Res 1999;44:121-131.
28. Yue L, Feng J, Gaspo R, Li GR, Wang Z, Nattel S: Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res 1997;81:512-525.
29. Nattel S: Therapeutic implications of atrial fibrillation mechanisms: can mechanistic insights be used to improve AF management? Cardiovasc Res 2002;54:347-360.
30. Nattel S: New ideas about atrial fibrillation 50 years on. Nature 2002;415:219-226.
31. Daoud EG, Bogun F, Goyal R, et al: Effect of atrial fibrillation on atrial refractoriness in humans. Circulation 1996;94:1600-1606.
32. Nattel S, Khairy P, Schram G: Arrhythmogenic ionic remodeling: adaptive responses with maladaptive consequences. Trends Cardiovasc Med 2001;11:295-301.
33. Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K: Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000;101:2612-2617.
34. Li DS, Fareh S, Leung TK, Nattel S: Promotion of atrial fibrillation by heart failure in dogs - Atrial remodeling of a different sort. Circulation 1999;100:87-95.
35. Li D, Shinagawa K, Pang L, et al: Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001;104:2608-2614.
36. Allessie M, Ausma J, Schotten U: Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 2002;54:230-246.
37. Shinagawa K, Shiroshita-Takeshita A, Schram G, Nattel S: Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: insights into the mechanism of the superior efficacy of amiodarone. Circulation 2003;107:1440-1446.
38. Nattel S, Khairy P, Roy D, et al: New approaches to atrial fibrillation management: a critical review of a rapidly evolving field. Drugs 2002;62:2377-2397.
39. Beck-da-Silva L, de Bold A, Fraser M, Williams K, Haddad H: Brain natriuretic peptide predicts successful cardioversion in patients with atrial fibrillation and maintenance of sinus rhythm. Can J Cardiol 2004;20:1245-1248.
40. Petersen P, Kastrup J, Vilhelmsen R, Schutten HJ: Atrial natriuretic peptide in atrial fibrillation before and after electrical cardioversion therapy. Eur Heart J 1988;9:639-641.
41. Goette A, Staack T, Rocken C, et al: Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000;35:1669-1677.
42. Goette A, Arndt M, Rocken C, et al: Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation 2000;101:2678-2681.
43. Mulrow PJ: Angiotensin II and aldosterone regulation. Regul Pept 1999;80:27-32.
44. Hollenberg NK, Chenitz WR, Adams DF, Williams GH: Reciprocal influence of salt intake on adrenal glomeralosa and renal vascular responses to angiotensin II in normal man. J Clin Invest 1974;54:34-42.
45. Lijnen P, Petrov V: Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol 2000;32:865-879.
46. Schmidt BM, Georgens AC, Martin N, et al: Interaction of rapid nongenomic cardiovascular aldosterone effects with the adrenergic system. J Clin Endocrinol Metab 2001;86:761-767.
47. Mizuno Y, Yoshimura M, Yasue H, et al: Aldosterone production is activated in failing ventricle in humans. Circulation 2001;103:72-77.
48. Ramires FJ, Mansur A, Coelho O, et al: Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol 2000;85:1207-1211.
49. MacFadyen RJ, Barr CS, Struthers AD: Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997;35:30-34.
50. Tuinenburg AE, van Veldhuisen DJ, Boomsma F, van den Berg MP, de Kam PJ, Crijns HJ: Comparison of plasma neurohormones in congestive heart failure patients with atrial fibrillation versus patients with sinus rhythm. Am J Cardiol 1998;81:1207-1210.
51. Berglund H, Boukter S, Theodorsson E, Vallin H, Edhag O: Raised plasma concentrations of atrial natriuretic peptide are independent of left atrial dimensions in patients with chronic atrial fibrillation. Br Heart J 1990;64:9-13.
52. Jayachandran JV, Sih HJ, Winkle W, Zipes DP, Hutchins GD, Olgin JE: Atrial fibrillation produced by prolonged rapid atrial pacing is associated with heterogeneous changes in atrial sympathetic innervation. Circulation 2000;101:1185-1191.
53. Goette A, Hoffmanns P, Enayati W, Meltendorf U, Geller JC, Klein HU: Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation. Am J Cardiol 2001;88:906-909.
54. Budaj A, Cybulski J, Cedro K, et al: Effects of captopril on ventricular arrhythmias in the early and late phase of suspected acute myocardial infarction. Randomized, placebo-controlled substudy of ISIS-4. Eur Heart J 1996; 17:1506-1510.
55. Ruilope LM, Barrios V, Volpe M: Renal implications of the renin-angiotensin-aldosterone system blockade in heart failure. J Hypertens 2000;18:1545-1551.
56. Kober L, Torp-Pedersen C, Carlsen JE, et al: A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333:1670-1676.
57. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C: Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999;100:376-380.
58. Vermes E, Tardif JC, Bourassa MG, et al: Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003;107:2926-2931.
59. Alsheikh-Ali AA, Wang PJ, Rand W, et al: Enalapril treatment and hospitalization with atrial tachyarrhythmias in patients with left ventricular dysfunction. Am Heart J 2004;147:1061-1065.
60. Maggioni AP, Latini R, Carson PE, et al: Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005;149:1-10.
61. Coletta AP, Cleland JG, Freemantle N, Loh H, Memon A, Clark AL: Clinical trials update from the European Society of Cardiology: CHARM, BASEL, EUROPA and ESTEEM. Eur J Heart Fail 2003;5:697-704.
62. Yusuf S, Pfeffer MA, Swedberg K, et al: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 2003;362:777-781.
63. Granger CB, McMurray JJ, Yusuf S, et al: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-776.
64. McMurray JJ, Ostergren J, Swedberg K, et al: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-771.
65. Pfeffer MA, Swedberg K, Granger CB, et al: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-766.
66. Michelson E, Swedberg K, Granger C, et al: Prevention of atrial fibrillation in symptomatic chronic heart failure by candesartan: results from CHARM (abstract). Program and Abstracts American College of Cardiology 53rd Annual Scientific Session, New Orleans, 2004.
67. Lindholm LH, Ibsen H, Dahlof B, et al: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-1010.
68. Wachtell K, Lehto M, Gerdts E, et al: Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005;45:712-719.
69. Mathew JP, Fontes ML, Tudor IC, et al: A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 2004;291:1720-1729.
70. Madrid AH, Bueno MG, Rebollo JM, et al: Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002;106:331-336.
71. Ueng KC, Tsai TP, Yu WC, et al: Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 2003;24:2090-2098.
72. Sinno H, Derakhchan K, Libersan D, Merhi Y, Leung TK, Nattel S: Atrial ischemia promotes atrial fibrillation in dogs. Circulation 2003;107:1930-1936.
73. Solti F, Vecsey T, Kekesi V, Juhasz-Nagy A: The effect of atrial dilatation on the genesis of atrial arrhythmias. Cardiovasc Res 1989;23:882-886.
74. Allessie MA, Boyden PA, Camm AJ, et al: Pathophysiology and prevention of atrial fibrillation. Circulation 2001;103:769-777.
75. Ravelli F, Allessie M: Effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in the isolated Langendorff-perfused rabbit heart. Circulation 1997;96:1686-1695.
76. Sanfilippo AJ, Abascal VM, Sheehan M, et al: Atrial enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study. Circulation 1990;82:792-797.
77. van Gelder IC, Crijns HJ, van Gilst WH, Hamer HP, Lie KI: Decrease of right and left atrial sizes after direct-current electrical cardioversion in chronic atrial fibrillation. Am J Cardiol 1991;67:93-95.
78. Li D, Melnyk P, Feng J, et al: Effects of experimental heart failure on atrial cellular and ionic electrophysiology. Circulation 2000;101:2631-2638.
79. Li D, Fareh S, Leung TK, Nattel S: Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 1999;100:87-95.
80. Nattel S: New ideas about atrial fibrillation 50 years on. Nature 2002;415:219-226.
81. Goette A, Staack T, Rocken C, et al: Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000;35:1669-1677.
82. Goette A, Arndt M, Rocken C, et al: Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation 2000;101:2678-2681.